Faron Pharmaceuticals: Approval to Initiate BEXMAB Study - Redeye

Faron announced earlier today that the company’s New Drug (IND) application to initiate the phase I/II BEXMAB study with lead candidate Bexmarilimab has been approved by both the US Food and Drug Administration (FDA) and the Finnish Medicines Agency (FIMEA).

Länk till analysen i sin helhet: https://www.redeye.se/research/842187/faron-pharmaceuticals-approval-to-initiate-bexmab-study?utm_source=finwire&utm_medium=RSS